tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

SWTX Stock Latest News

SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
Press ReleasesSpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
3d ago
SWTX
SpringWorks Therapeutics completes submission of NDA for mirdametinib
PremiumThe Fly
SpringWorks Therapeutics completes submission of NDA for mirdametinib
25d ago
SWTX
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
PremiumPress Releases
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
25d ago
SWTX
SpringWorks Therapeutics’ Collaboration with GSK Ends
PremiumCompany Announcements
SpringWorks Therapeutics’ Collaboration with GSK Ends
2M ago
8K
SWTX
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PremiumPress Releases
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
2M ago
SWTX
SpringWorks Therapeutics announces Phase 2b ReNeu trial data for ASCO
PremiumThe FlySpringWorks Therapeutics announces Phase 2b ReNeu trial data for ASCO
2M ago
SWTX
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
PremiumPress Releases
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
2M ago
SWTX
SpringWorks Therapeutics price target raised to $77 from $75 at JPMorgan
PremiumThe Fly
SpringWorks Therapeutics price target raised to $77 from $75 at JPMorgan
3M ago
SWTX
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
PremiumPress Releases
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
3M ago
SWTX
3 Best Stocks to Buy Now, 5/3/2024, According to Top Analysts 
PremiumMarket News
3 Best Stocks to Buy Now, 5/3/2024, According to Top Analysts 
3M ago
CZR
SYM
SpringWorks Therapeutics reports Q1 EPS ($1.18), consensus ($1.18)
PremiumThe Fly
SpringWorks Therapeutics reports Q1 EPS ($1.18), consensus ($1.18)
3M ago
SWTX
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
PremiumPress Releases
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
3M ago
SWTX
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
PremiumPress ReleasesSpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
3M ago
SWTX
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
PremiumPress Releases
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
3M ago
SWTX
SpringWorks Therapeutics price target raised to $74 from $73 at JPMorgan
PremiumThe Fly
SpringWorks Therapeutics price target raised to $74 from $73 at JPMorgan
5M ago
SWTX
SpringWorks Therapeutics submits rolling NDA to FDA for mirdametinib
PremiumThe Fly
SpringWorks Therapeutics submits rolling NDA to FDA for mirdametinib
5M ago
SWTX
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
PremiumPress Releases
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
5M ago
SWTX
3 Best Stocks to Buy Now, 3/1/2024, According to Top Analysts 
PremiumMarket News
3 Best Stocks to Buy Now, 3/1/2024, According to Top Analysts 
5M ago
IAS
DCGO
SpringWorks Therapeutics announces EMA validaion for nirogacestat MAA
PremiumThe Fly
SpringWorks Therapeutics announces EMA validaion for nirogacestat MAA
5M ago
SWTX
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
PremiumPress ReleasesSpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
5M ago
SWTX
SpringWorks Therapeutics price target raised to $63 from $47 at Barclays
PremiumThe Fly
SpringWorks Therapeutics price target raised to $63 from $47 at Barclays
5M ago
SWTX
SpringWorks Therapeutics price target raised to $59 from $54 at Goldman Sachs
PremiumThe Fly
SpringWorks Therapeutics price target raised to $59 from $54 at Goldman Sachs
5M ago
SWTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >